Board Change • May 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 11 non-independent directors. Director Haitham Mohammed Masrouji was the last director to join the board, commencing their role in 2026. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Apr 18
Jerusalem Pharmaceuticals Co. Ltd. Announces Board Changes Jerusalem Pharmaceuticals Co. Ltd. announced that at the ordinary General Assembly meeting held on April 15, 2026, Approval of the resignation of Dr. Samir Al-Khatib from the Board of Directors and was replaced by Dr. Haitham Masrouji as a member of the Board of Directors. 공시 • Mar 31
Jerusalem Pharmaceuticals Co. Ltd. to Report Q1, 2026 Results on Apr 15, 2026 Jerusalem Pharmaceuticals Co. Ltd. announced that they will report Q1, 2026 results on Apr 15, 2026 공시 • Mar 18
Jerusalem Pharmaceuticals Co. Ltd. announces Annual dividend Jerusalem Pharmaceuticals Co. Ltd. announced Annual dividend of USD 0.1500 per share, ex-date on April 16, 2026 and record date on April 19, 2026. 공시 • Mar 12
Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 15, 2026 Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 15, 2026. Location: ramallah Palestinian Authority 공시 • Feb 25
Jerusalem Pharmaceuticals Co. Ltd. to Report Fiscal Year 2025 Results on Mar 10, 2026 Jerusalem Pharmaceuticals Co. Ltd. announced that they will report fiscal year 2025 results on Mar 10, 2026 공시 • Dec 17
Jerusalem Pharmaceuticals Co. Ltd. to Report First Half, 2025 Results on Dec 29, 2025 Jerusalem Pharmaceuticals Co. Ltd. announced that they will report first half, 2025 results on Dec 29, 2025 Board Change • Jun 10
No independent directors There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Deputy Chairman Iyad Masrouji was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. 공시 • Apr 15
Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 29, 2025 Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Apr 29, 2025. Location: ramallah Palestinian Authority 공시 • Mar 22
Jerusalem Pharmaceuticals Co. Ltd. announces Annual dividend, payable on June 29, 2025 Jerusalem Pharmaceuticals Co. Ltd. announced Annual dividend of USD 0.0800 per share payable on June 29, 2025, ex-date on April 30, 2025 and record date on May 04, 2025. 공시 • Mar 21
Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Mar 19, 2025 Jerusalem Pharmaceuticals Co. Ltd., Annual General Meeting, Mar 19, 2025. Location: ramallah Palestinian Authority Board Change • Feb 12
No independent directors There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Deputy Chairman Iyad Masrouji was the last director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Aug 16
Second quarter 2024 earnings released: EPS: US$0.053 (vs US$0.083 in 2Q 2023) Second quarter 2024 results: EPS: US$0.053 (down from US$0.083 in 2Q 2023). Revenue: US$8.68m (down 7.0% from 2Q 2023). Net income: US$953.3k (down 36% from 2Q 2023). Profit margin: 11% (down from 16% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 10% per year. Reported Earnings • Jun 16
First quarter 2024 earnings released: EPS: US$0.015 (vs US$0.082 in 1Q 2023) First quarter 2024 results: EPS: US$0.015 (down from US$0.082 in 1Q 2023). Revenue: US$7.90m (down 16% from 1Q 2023). Net income: US$273.0k (down 82% from 1Q 2023). Profit margin: 3.5% (down from 16% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • May 14
Upcoming dividend of US$0.10 per share Eligible shareholders must have bought the stock before 21 May 2024. Payment date: 21 July 2024. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.0%). Higher than average of industry peers (1.9%). Board Change • Jan 15
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Nov 04
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Aug 12
Second quarter 2023 earnings released: EPS: US$0.083 (vs US$0.063 in 2Q 2022) Second quarter 2023 results: EPS: US$0.083 (up from US$0.063 in 2Q 2022). Revenue: US$9.33m (down 10% from 2Q 2022). Net income: US$1.49m (up 33% from 2Q 2022). Profit margin: 16% (up from 11% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Board Change • Jul 11
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • May 31
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Upcoming Dividend • Apr 11
Upcoming dividend of US$0.15 per share at 2.9% yield Eligible shareholders must have bought the stock before 18 April 2023. Payment date: 18 June 2023. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 2.9%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.1%). Higher than average of industry peers (1.8%). Board Change • Jan 18
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Nov 17
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Oct 07
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Jun 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • May 05
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. No independent directors (10 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Upcoming Dividend • Apr 05
Upcoming dividend of US$0.12 per share Eligible shareholders must have bought the stock before 12 April 2022. Payment date: 12 June 2022. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (5.1%). Higher than average of industry peers (1.7%). Board Change • Jan 10
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. No independent directors (11 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Upcoming Dividend • May 23
Upcoming dividend of US$0.08 per share Eligible shareholders must have bought the stock before 30 May 2021. Payment date: 26 July 2021. Trailing yield: 3.4%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.0%). Higher than average of industry peers (1.4%). Is New 90 Day High Low • Mar 11
New 90-day high: US$2.88 The company is up 3.0% from its price of US$2.80 on 02 December 2020. The Palestinian Territory, Occupied market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period. Is New 90 Day High Low • Dec 20
New 90-day high: US$2.85 The company is up 14% from its price of US$2.50 on 22 September 2020. The Palestinian Territory, Occupied market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period. Is New 90 Day High Low • Nov 12
New 90-day high: US$2.60 The company is up 5.0% from its price of US$2.47 on 12 August 2020. The Palestinian Territory, Occupied market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period. Is New 90 Day High Low • Oct 22
New 90-day high: US$2.58 The company is up 7.0% from its price of US$2.41 on 21 July 2020. The Palestinian Territory, Occupied market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period.